Global Urinary Tract Infection Treatment Industry to US$13.6 billion by 2034, fueled by new drug development | Reports By FMI ...

PTEN stock results show that Patterson-UTI Energy beat analyst estimates for earnings per share but missed on revenue for the ...

Warning! GuruFocus has detected 4 Warning Sign with PTEN. Patterson-UTI Energy Inc (NASDAQ:PTEN) disclosed its financial results for the first quarter ended March 31, 2024, through its 8-K filing on ...

A study in eClinicalMedicine explores the relationship between gut microbiota, urinary tract colonization, and recurrent ...

Q1 Non-GAAP EPS of $0.15 beats by $0.03. Revenue of $1.5B (+89.4% Y/Y) misses by $20M. Adjusted EBITDA of $375 million. Cash from Operations of..

More than 50% of the patients who used a new mouth-spray-based vaccine didn't have a UTI for up to nine years.

A woman who spent years in pain has spoken of the symptoms she experienced before being finally diagnosed with recurrent UTI ...

The results matched Wall Street expectations. The average estimate of 10 analysts surveyed by Zacks Investment Research was also for earnings of 13 cents per share. The provider of onshore contract ...

Select "Add to Compare" to begin comparing Stocks, ETFs, Mutual Funds and more.

The Food and Drug Administration (FDA) has approved Pivya (pivmecillinam) for the treatment of female patients 18 years of age and older with uncomplicated urinary tract infections (UTIs) caused by ...

For non-critically ill patients with urinary tract infection (UTI), computerized provider order entry (CPOE) prompts ...

Prabhudas Lilladher is bullish on UTI Asset Management Company has recommended buy rating on the stock with a target price of ...